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Introduction. Adherence to antiretroviral therapy (ART) in low-income countries is mainly assessed by self-reported adherence
(S-RA) without drug level determination. Nonadherence is an important factor in the emergence of resistance to ART, presenting
a need for drug level determination. Objective. We set out to establish the relationship between plasma stavudine levels and S-RA
and validate S-RA against the actual plasma drug concentrations. Methods. A cross-sectional investigation involving 234 patients
in Uganda. Stavudine plasma levels were determined using high-performance liquid chromatography. We compared categories of
plasma levels of stavudine with S-RA using multivariable logistic regression models. Results. Overall, 194/234 patients had S-RA ≥
95% (good adherence) and 166/234 had stavudine plasma concentrations ≥ 36nmol/L (therapeuticconcentration). Patients with
good S-RA were eight times more likely to have stavudine levels within therapeutic concentration (Adjusted Odds Ratio: 7.7, 95%
Conﬁdence Interval: 3.5–7.0). However, of the 194 patients with good S-RA, 21.7% had below therapeutic concentrations. S-RA
had high sensitivity for adherence (91.6%), but limited speciﬁcity for intrinsic poor adherence (38.2%). Conclusions.S - R Ai sa
good tool for assessing adherence, but has low speciﬁcity in detecting nonadherence, which has implications for emergence of
resistance.
1.Introduction
The role of good adherence in the attainment of positive
clinical outcomes among HIV-infected patients on the life-
long antiretroviral therapy (ART) has been well demon-
s t r a t e di np r e v i o u ss t u d i e s[ 1, 2]. Good adherence has
been associated with suppression of the virus, reduction
in resistant strains of HIV, delayed progression to AIDS,
and improved quality of lifeand reduction in AIDS-related
mortality,amongotherbeneﬁts[3–14].Globally,suboptimal
or poor adherence levels to ART are associated with poor
viral suppression and rebound plasma viremia, which leads
to emergency of drug resistant HIV strains, increasing risk
of transmission of multidrug resistant viruses within the
population [15]. Studies conducted around the world have
reported adherence rates ranging between 40–70% including
a rate of 68% for Uganda [15–17].
Accurate assessment of patient adherence to antiretrovi-
ral medication is critical to maintain the ART beneﬁts and
reduce the risks associated with poor adherence. Among2 ISRN Pharmacology
treatment centres within sub-Saharan Africa, adherence is
assessed using various methods including patients’ self-
reports, announced or unannounced pill counts, use of
pharmacy reﬁll records, compliance to clinical appoint-
ments, medication diaries, linear analog scales, electronic
monitoring systems, and sometimes measurement of plasma
drug levels [18–20]. However, nearly all these methods are
associated with known limitations [16, 21–23] and thus fail
to capture the important dimensions of adherence, which is
not commonly done in resource limited countries [22].
In Uganda, adherence to ART is commonly assessed
using self-report adherence (S-RA). Recent literature has
shown diverse views about the degree of reliability of S-RA
[24].Furthermore,limitedinformationisavailableregarding
the sensitivity and speciﬁcity of this adherence assessment
method validated using plasma drug concentration levels. In
the current study, we aimed at establishing the relationship
between plasma drug levels and adherence levels determined
by S-RA among HIV/AIDS patients on stavudine-containing
regimen in Uganda.
2. Methods
2.1. Study Site and Design. This was a cross-sectional study
of patients attending the ART clinic at the Joint Clinical
Research Centre (JCRC) in Kampala, Uganda. The study
was conducted between June 2006 and June 2007, recruited
patientswereaged18to50years,whohadbeenontreatment
for at least three months and were willing to give a written
consent. At the JCRC clinic, patients on ART are assessed
for S-RA at every visit by an adherence counselor basing on
the number of pills reported to have been taken. A patient
is classiﬁed to be adherent to ART if their S-RA is 95%
or more. Their CD4 counts are also measured at initiation
of therapy and then once every six months, as part of the
routinemonitoringactivities.Thesedatasetsarerecordedon
theirclinicalchartsandlaterstoredinanelectronicdatabase.
2.2. Sample Size Calculations and Inclusion Criteria. Given
the diversity in the characteristics of patients attending the
JCRC clinic, we anticipated their adherence levels to be a
little lower than the global adherence levels of 70%, but
within Uganda’s adherence levels of 68% as documented in
other studies [15–17]. In our power calculations, we used
the formula for computing proportions of sample sizes as
documented by Schaeﬀer et al. (1990) [25], which gives
similarresultstotheKishetal.(1965)formula[26].Withthe
assumption of a 68% adherence rate among the 750 patients
on ART, on average, who attended the clinic weekly in 2006,
the study would be suﬃciently powered to detect a 5% eﬀect
if 232 participants would be recruited. In the end, however,
thisstudyrecruited234patients,whowereontheTriomune-
30regimenforatleastthreemonthsandhadconsistentS-RA
assessments during the last three clinic encounters. Clients
who had taken their last medication dose before consent
or were not willing to consent for a blood draw or were
taking concomitant medication which was likely to interfere
withthebioavailabilityofstavudinesuchasmethadone,were
excluded from participating.
2.3. Data Collection. Demographic, clinical, and S-RA data
were extracted from the patient records using a check list.
Patients with mean S-RA of 95% and above on the past
three clinic visits were classiﬁed as adherent, whereas those
with mean S-RA below 95% within the same duration were
classiﬁed as nonadherent. Predose venous blood samples
(4mls) from each participant were collected in prelabeled
EDTA vacutainer for plasma drug level analysis.
2.4. Laboratory Procedures. Reference stavudine and the
internal standard (thymidine oxetane) were obtained from
Bristol-Myers Squibb. Distilled water was obtained from
Mili-Q water puriﬁcation system. The analytical column was
aN o v ap a kC 18 5micro meter particle size, 150 × 3.9mm
(Waters)withaguardcolumnNovapakC18 (Waters).Varian
solid-phase extraction cartridges (Varian, Netherlands: part
no. 12102028 lot number 0715906, code 33106t phase C18,
3cc 500mg) were used for extraction of the drugs from the
plasmasamples.HPLC-gradeacetonitrileandmethanolwere
purchased from BDH (U) Limited, Kampala. Blank plasma
was obtained from the Uganda Blood Bank, Nakasero,
Kampala.
Stavudine stock solution of 1.5mg was prepared in
10mL methanol, with serial dilutions with distilled water,
to provide solutions of 10µg to 550µg/mL. Calibration
concentrationsof35,50,78,312,625,1250,and2500nmol/L
in blank plasma were used to construct the standard
curve from the stock solution. A second stock solution of
stavudine was used to prepare the quality control standards
in plasma. All the calibration and the quality control
standards were contained in polypropylene microtubes and
stored at −70◦C until assay. Stock solution of internal
standard of 1mg/mL was prepared in methanol and diluted
to 100µg/mL in 50% methanol. The mobile phase com-
prised of 0.01M ammonium acetate:acetonitrile:methanol
(80:10:10, V/V/V (%)) at a ﬂow rate of 1.2mL/min.
Plasma concentrations of stavudine were determined
according to the method described by Sarasa et al. [27]u t i -
lizing a validated high-performance liquid chromatographic
(HPLC)separation[28].Aliquotsof200µLofthawedpatient
plasma samples were added to the solid-phase cartridges and
allowed to pass through the cartridge bed into clean dry
glass tubes and then washed with two 1-mL water aliquots.
The cartridge bed was then dried by gentle suction. The
stavudine was eluted from the solid-phase cartridge with
1mLofmethanol.Theeluentwasthenevaporatedtodryness
under nitrogen stream. The residue was reconstituted with
65µL of the mobile phase, vortexed and 50µL of this sample
was injected onto the HPLC system. Chromatograph curve
peak heights were plotted against concentration to generate
the standard curves.
The accuracy and interday precision of the method
were estimated by assaying ﬁve replicate plasma samples at
diﬀerent concentrations, in three runs. The overall mean
precision was deﬁned by the coeﬃcient of variation set atISRN Pharmacology 3
2.5% from ﬁve standards of three diﬀerent concentrations
analyzed on the same day. Recovery of the study drug after
the solid phase extraction was determined by comparing
the observed stavudine concentrations in the extracted
plasma, to those of nonprocessed standard solutions. Any
possible interference from the endogenous compounds was
investigated by the analysis of six diﬀerent blank matrices.
A l lr e a g e n t sw e r eo fH P L Cg r a d e .
2.5. Statistical Methods. Plasma stavudine concentrations
analyzed ranged from zero to 4254nmol/L. The steady
state pharmacokinetic parameters of stavudine 30mg in
HIV-infected adults ranges between 8 ± 2ng/mL (35.7 ±
8.9nmol/L) and 536 ± 454ng/mL (2392.9 ± 2026.8nmol/L)
[29]. Patients with 95% and above self-reported adher-
ence levels are expected to have a trough plasma drug
concentration of not less than 36nmol/L. The 36nmol/L
is the documented cutoﬀ for the lower boundary normal
stavudine therapeutic concentrations [29]. A binary variable
was created, indicating whether each patient’s plasma drug
concentrations were below 36nmol/L or not, and this
was the outcome of interest. In this analysis, the primary
independentvariablewasthebinaryS-RAvariableindicating
whether the patient was 95% and above adherent to ART or
not.
In comparative analyses, the Chi-square test was used to
investigate the association between all categorical covariates
and the outcome. For continuous variables which were
normally distributed, the student t-test with equal variances
was used to compare means within the outcome categories.
The primary aim of this analysis was to determine the
association between stavudine plasma concentrations and S-
RA.ThiswasachievedinclassicalMantelHaenszel(MH)and
logistic regression models. Crude associations between all
categorical exposures and the outcome were determined in
univariate logistic models, where statistical signiﬁcance was
assessed using the global likelihood ratio test. Confounding
bias introduced in the crude association between plasma
concentrations and S-RA from other patient-level covariates
was assessed in multivariable logistic regression models.
Here, the joint Wald test was used to assess statistical
signiﬁcance. Eﬀects modiﬁcation was also investigated in
these models.
The secondary aim of this analysis was to validate S-RA
against the actual-detected plasma drug concentrations. This
was achieved by computing the sensitivity, speciﬁcity, and
negative and positive predictive values.
All analyses were performed using Stata 11/IC (Stata
Corp, College Station, TX, USA), all P values were based on
the 5% level of precision and all tests were two-tail based.
2.6. Ethical Considerations. All participants gave a written
consent. The study protocol was approved by the Faculty
of Medicine Research and Ethics Committee, Makerere
University and the JCRC Institutional Review Board, while
permission to conduct the study was granted by the Uganda
National Council of Science and Technology.
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Figure 1: The broken horizontal lines indicate the 36 to
2400nmol/L normal range levels of stavudine concentrations in
steady state. The boxes indicate the lower quartile (Q1), the
median (Q2), and upper quartile (Q3) limits of the concentrations,
respectively.TheupperandlowerlimitsoftheWhiskersindicatethe
minimumandmaximumobservations,whereasthedotsaboveeach
upper cap of the whisker represent the concentrations considered to
be outliers.
3. Results
All data from the 234 recruited patients were included in the
ﬁnalanalysis.Alcoholconsumptiondatawasmissingforfour
patients, CD4 measurements were missing for 65 patients,
and body weight information was missing for nine patients.
While ﬁtting the models, records with missing data were
automatically excluded.
Overall, 194/234 (82.9%) patients reported S-RA of 95%
and above. The median plasma stavudine concentration for
all patients was 517.9nmol/L (range: 0, 4253.8, Interquartile
Range: 0, 1183.0). Overall, 68/234 (29.1%) patients had
stavudine plasma concentrations less than 36nmol/L (clas-
siﬁed as below therapeutic range), whereas 166/234 (70.9%)
had stavudine plasma concentrations that were 36nmol/L
and above (classiﬁed as within or above therapeutic range).
Figure 1 shows the distribution of plasma levels of stavudine
among patients with S-RA below 95%, compared to those
with S-RA of 95% and above. The broken horizontal lines
indicate the 36 to 2400nmol/L normal range levels of stavu-
dine concentrations in steady state. The boxes indicate the
lower-quartile (Q1), the median- (Q2), and upper-quartile
(Q3) limits of the concentrations respectively. The upper
and lower limits of the Whiskers indicate the minimum and
maximum observations, whereas the dots above each upper
cap of the whisker represent the concentrations considered
to be outliers.
Table 1 presents the distribution of S-RA, demographic
and clinical characteristics by plasma drug concentration
classiﬁcation. Most 152/194 (78.4%) patients with S-RA of
9 5 %a n da b o v ew e r ef o u n dt oh a v ew i t h i no ra b o v en o r m a l
therapeutic concentrations of stavudine (P<0.0001). How-
ever, 42/194 (21.7%) of patients reporting good adherence
actually had below normal drug concentrations. In unad-
justed models, patients who reported 95% and above S-RA4 ISRN Pharmacology
Table 1: The association between patients’ demographic/clinical characteristics and plasma drug therapeutic concentration among patients
on a stavudine-containing regimen in Uganda.
Plasma drug concentration Crude association
Below normal range1 Within or above normal range2 Odds ratio (95%CI) P-value
Self-report
Adherence
Below 95% (n = 40) 26 (65.0%) 14 (35.0%) [reference] <0.0001
95% and above (n = 194) 42 (21.7%) 152 (78.4%) 6.72 (3.06, 14.78)
Gender Male (n = 84) 23 (27.4%) 61 (72.6%) [reference] 0.6728
Female (n = 150) 45 (30.0%) 105 (70.0%) 0.88 (0.49, 1.59)
Age in years Mean (SD) 38.4 (7.0) 38.6 (6.9) 1.00 (0.96, 1.05) 0.833
Employment status Not Employed (n = 96) 23 (24.0%) 73 (76.0%) [reference] 0.2079
Employed (n = 133) 42 (31.6%) 91 (68.4%) 0.68 (0.38, 1.24)
Marital Status Not married (n = 106) 24 (22.6%) 82 (77.4%) [reference] 0.0496
Married (n = 128) 44 (34.4%) 84 (65.6%) 0.56 (0.31, 1.01)
Education No Education (n = 16) 5 (31.3%) 11 (68.8%) [reference] 0.8419
Some Education (n = 218) 63 (28.9%) 155 (71.1%) 1.12 (0.37, 3.36)
Alcohol drinking
status
Never (n = 144) 42 (29.2%) 102 (70.8%) [reference] 0.7946
Stopped drinking (n = 26) 8 (30.8%) 18 (69.2%) 0.93 (0.37, 2.29)
Still drinking (n = 60) 15 (25.0%) 45 (75.0%) 1.24 (0.62, 2.45)
Current CD4
count in cells/mL Mean (SD) 289 (180) 292 (141) 1.00 (1.00, 1.00) 0.916
Body weight in kgs Mean (SD) 61.9 (9.9) 62.9 (10.0) 1.01 (0.98, 1.04) 0.520
1Stavudine plasma concentration below 36nM/mL
2Stavudine plasma concentration 36nM/mL and above.
Table 2: Multivariate models explaining the association between
plasma drug therapeutic concentrations and self-report adherence
adjustedfordemographic/clinicalcharacteristicsamongpatientson
a stavudine-containing regimen in Uganda.
Adjusting variable
Adjusted association between
plasma drug concentration
and self-reported adherence
Adjusted odds ratio
(95% CI) P-value
None [crude association] 6.72 (3.06, 14.78) <0.0001
Gender 7.13 (3.18, 16.01) <0.0001
Age in years 6.72 (3.22, 14.01) <0.0001
Employment status 6.54 (2.92, 14.65) <0.0001
Marital status 6.56 (2.98, 14.41) <0.0001
Education 6.75 (3.06, 14.87) <0.0001
Alcohol drinking status 6.94 (3.10, 15.52) <0.0001
Current CD4 count in
cells/mL 7.34 (3.39, 15.87) <0.0001
Body weight in kgs 8.49 (3.21, 22.46) <0.0001
were almost seven times more likely to have within or above
therapeutic plasma stavudine concentrations, compared to
those who reported less than 95% S-RA (crude odds ratio:
6.72, 95% conﬁdence interval (CI): 3.06 to 14.78).
Table 2 presents results from multivariable models to
determine the association between plasma stavudine con-
centration and S-RA, after adjusting for each demographic
and clinical characteristic. We detected no evidence of eﬀects
modiﬁcation from any of the independent study covariates.
The ﬁnal model was adjusted for gender and body weight,
where patients who reported 95% and above S-RA were
almost eight times more likely (Adjusted Odds Ratio: 7.7,
95% CI: 3.5 to 7.0, P<0.0001) to have within or above
therapeutic plasma stavudine concentrations, compared to
those who reported less than 95% S-RA.
In this population, the sensitivity and speciﬁcity of S-
RA in determining actual adherence measured by the plasma
concentration of stavudine within the therapeutic range was
91.6% and 38.2%, respectively, while the respective positive
and negative predictive values were computed as 78.4% and
65.0%.
4. Discussion
Thepresentstudyfoundthatslightlyover80%ofthepatients
reported to be adherent (S-RA ≤ 95%) to ART, a ﬁnding
consistent with what has been reported elsewhere [15–17].
We also found out that patients with good S-RA were
almost seven to eight times more likely to have therapeutic
drug levels within or above therapeutic range. This positive
association is critical for treatment success [1, 2, 30, 31].
However, 21.7% of patients reporting good adherence
actually had insuﬃcient plasma drug concentrations (false
positives) (Table 1). These results reveal that, whereas high
S-RA rates to ART correlated well with normal therapeutic
plasma drug levels among these patients, S-RA as a tool
may have some limitations while identifying nonadherent
patients. The speciﬁcity calculations implied that, for trueISRN Pharmacology 5
nonadherent patients assessed for ART adherence, the S-
RA method is cable of identifying only 38 out of every one
hundred nonadhering patients. The false positives subgroup
of “good S-RA, but poor drug levels” would thus constitute
thecategory of “intrinsic poor adherence”. These may have
higher risks of contributing to emergence of resistance to
antiretroviral therapy. Furthermore, the pharmacokinetic
characteristics of this group of patients need to be investi-
gated, especially their variability of stavudine metabolism. It
may be possible that these are fast metabolizers of stavudine,
hence presenting with low plasma concentrations.
Out of the 40 S-RA nonadherent participants in this
study, 14 (35.0%) had plasma stavudine concentrations
within or above normalrange (Table 1). This may be
attributedtothefactthat,priortosamplecollection,patients
may have taken their dose for that morning, even though
they might have been classiﬁed as nonadherent according to
the three-month S-RA calculations. Alternatively, this ﬁnd-
ing may be attributed to pharmacokinetic factors, including
the fact that these patients may be slow ART metabolizers,
which is linked to genetic variability [32, 33]. These false
negatives do present an opportunity for further scientiﬁc
investigations.
Generally, nonadherence to ART has been viewed as
a signiﬁcant public health concern based on the percep-
tion that nonadherence would speed the development and
transmission of drug-resistant strains to the masses [2,
3, 11]. However, while focus of interventions to address
nonadherenceisaimedatpopulationsthoughttohavelowest
adherence rates, these are sometimes not the populations
in which actual resistance occurs [34]. The existence of
virologic failures among adhering patients may need further
scientiﬁcinvestigations[35].Ourrecommendationwouldbe
to encourage patient care providers, main stake holder min-
istries,andlegislatorsinSub-SaharanAfricaintoconsidering
occasional drug bioavailability monitoring to ensure success
of ART programs in the region.
Recently, there has been increasing recognition of proper
and adequate adherence assessment as a crucial factor in
improving treatment outcomes [11]. In this investigation,
we recognize that improving adherence and subsequently
treatment outcomes will require a combination of methods
appropriate to the patient and clinical settings [22, 36].
Timely interventions should include dedicated educational
and collaborative eﬀorts oﬀered to every patient, and adher-
encemonitoringinthehomesettingbycommunityoutreach
programs. In this way, the true nonadherent patients will
quickly be identiﬁed for timely intervention to improve their
adherence rates even where drug level analysis is not possible
such as in resource-limited countries like Uganda.
5. Conclusions
Patients who report high S-RA are most likely to adhere
to therapy, but some of them were probably nonadherent
basing on the suboptimal plasma drug levels, indicating that
S-RA lacks suﬃcient speciﬁcity for detecting nonadherence.
We thus recommend that, whenever possible drug level
determination should be performed since use of S-RA may
result in failure to identify the non adherent patients which
could have potential implications for drug resistance. Since
some patients in this study showed very high levels of the
drug in plasma, drug level determination would be necessary
in patients who show signs of adverse eﬀect to ART before
switching medication.
Limitationsof the Study
The cross-sectional study design provided no opportunity
for a complete measurement of all CD4 cell counts and to
monitorallpatients’bodyweightgain,asmeasuresofclinical
response to therapy.
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